Literature DB >> 27784439

[Development of CalliSpheres® embolic microspheres].

Y S Guan1, Q He1, Y Jin2, F Yao3.   

Abstract

CalliSpheres® embolic microspheres for embolization of the vasculature of liver cancer are designed, manufactured, and verified, in order to improve the effect of transcatheter arterial chemoembolization in the treatment of primary liver cancer.

Entities:  

Mesh：

Year:  2016        PMID： 27784439     DOI： 10.3760/cma.j.issn.1007-3418.2016.07.016

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN： 1007-3418


  12 in total

1.  CalliSpheres® microspheres drug-eluting bead transhepatic artery chemoembolization with or without sorafenib for the treatment of large liver cancer: a multi-center retrospective study.

Authors:  Song Liu; Guangji Yu; Qingdong Wang; Long Li; Ying Liu; Ke Du; Fei Zhang; Bangli Zhao; Guangsheng Zhao
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Efficacy and safety of drug-eluting beads for transarterial chemoembolization in patients with advanced hepatocellular carcinoma.

Authors:  Wen-Zhen Cao; Zhu-Qian Zhou; Song Jiang; Hao Li; Wei Niu; Peng Gao; Gui-Jie Li; Feng Chen
Journal:  Exp Ther Med       Date:  2019-11-01       Impact factor: 2.447

3.  Arsenic trioxide-loaded CalliSpheres: In vitro study of drug release and antitumor activity, and in vivo study of pharmacokinetics, treatment efficacy and safety in liver cancer.

Authors:  Xuhua Duan; Guorui Zhao; Xinwei Han; Jianzhuang Ren; Hao Li; Pengfei Chen; Manzhou Wang; Shuguang Ju
Journal:  Oncol Rep       Date:  2021-05-13       Impact factor: 3.906

4.  Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers.

Authors:  Shuisheng Zhang; Can Huang; Zhengzheng Li; Yongjie Yang; Tingting Bao; Haibo Chen; Yinghua Zou; Li Song
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

5.  CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma.

Authors:  Hua Xiang; Lin Long; Yuanhui Yao; Zhiyong Fang; Zhiming Zhang; Yongjin Zhang
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

6.  Comparison of chemoembolization with CalliSpheres® microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study.

Authors:  Bin Liang; Hua Xiang; Cong Ma; Bin Xiong; Yilong Ma; Chang Zhao; Yuanhui Yao; Zishu Zhang; Changyong Chen; Haiping Li; Qingyun Long; Jun Zhou; Chao Luo; Huaiming Qiu; Hongyao Hu; Hui Zhao; Guofeng Zhou; Chuansheng Zheng
Journal:  Cancer Manag Res       Date:  2020-02-10       Impact factor: 3.989

7.  Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres® Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis.

Authors:  Bin Liang; Joyman Makamure; Shenglei Shu; Lijie Zhang; Tao Sun; Chuansheng Zheng
Journal:  Front Oncol       Date:  2021-03-16       Impact factor: 6.244

8.  Optimized Loading of Idarubicin in CalliSpheres® Drug-Eluting Beads and Characterization of Release Profiles and Morphological Properties.

Authors:  Enhao Lu; Guoliang Shao; Jingqin Ma; Yiwei He; Yuanchuan Gong; Zhiping Yan; Xianyi Sha
Journal:  Pharmaceutics       Date:  2021-05-27       Impact factor: 6.321

9.  Transarterial chemoembolization with medium-sized doxorubicin-eluting Callisphere is safe and effective for patients with hepatocellular carcinoma.

Authors:  Cao-Ye Wang; Jin-Guo Xia; Zheng-Qiang Yang; Wei-Zhong Zhou; Wen-Hua Chen; Chun-Jian Qi; Jian-Ping Gu; Qi Wang
Journal:  Sci Rep       Date:  2020-03-10       Impact factor: 4.379

10.  Comparison of liver function and safety in hepatocellular cancer patients treated with DEB-TACE and cTACE: a multi-center, retrospective cohort study.

Authors:  Hua Xiang; Bin Xiong; Haiping Li; Chang Zhao; Zishu Zhang; Cong Ma; Chuansheng Zheng; Chao Luo; Huaiming Qiu; Yuanhui Yao; Hongyao Hu; Hui Zhao; Qingyun Long; Jun Zhou; Changyong Chen; Yilong Ma
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.